Hon. Deanna Tanner Okun

Deanna Tanner Okun is the managing partner at AMS TRADE LLP. She is an international trade attorney providing legal and strategic international trade policy advice to steer companies through the intersection where innovation confronts barriers, such as intellectual property theft, unfair trade practices, and regulatory hurdles. Her practice involves all aspects of unfair trade litigation and trade remedy advocacy. Her Section 337 work includes all stages of litigation at the U.S. International Trade Commission (ITC) from pre-institution consultation to post-remedy enforcement with Customs and Border Protection. She also represents companies in Title VII antidumping and countervailing duty investigations before the ITC and the Department of Commerce. In 2017, her client secured the first negative preliminary AD/CVD determination in over seven years and her work in trade remedy proceedings on behalf of U.S. companies extends to previously rarely used trade statutes, including Section 201, 232, and 301 investigations. She works closely with contacts in the executive, judicial, and legislative branches of the government to create innovative solutions to her clients’ legal and business challenges.

During her tenure as an ITC Commissioner, Deanna was nominated to be Deputy United States Trade Representative. In 2012, she was named Outstanding Woman of the Year by the Association of Women in International Trade (WIIT). She has served on the Federal Circuit Advisory Council since 2013. In 2019, for the seventh consecutive year, Managing Intellectual Property named Deanna one of the Top 250 Women in IP. She is also on the 2021-2022 USMCA Binational Panel Roster.

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More

Intellectual Property Rights and the Future of U.S. Technological Leadership

By Dr. Kirti Gupta This commentary is part of a report from the CSIS Economic Security and Technology Department, titled Staying Ahead in the Global Technology Race. The report features a set of essays outlining key issues on economic security for the next administration, including global technology competition, industrialization
Read More